Q3 2025 · 13F-HR
NVP Associates, LLCholdings as filed
Filed 2025-11-14 · accession 0001545692-25-000005
$166.1M
Reported value
5
Positions
2025-09-30
Period end
The Brief · NVP Associates, LLC · Q3 2025
AI · grounded in 13F
NVP Associates, LLC closed its position in DAVE, reducing its holdings by $62.45M. The fund also exited its position in OPEN, resulting in a decrease of $2.23M. These moves brought the fund's total assets under management to $166.05M across five positions.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 68170A108 | OMDA | OMADA HEALTH INC | $56.0M | 33.7% | 2,531,000 | Common | SOLE |
| 98937L105 | ZBIO | ZENAS BIOPHARMA INC | $40.8M | 24.6% | 1,838,482 | Common | SOLE |
| 55287L101 | MBX | MBX BIOSCIENCES INC | $37.4M | 22.5% | 2,136,335 | Common | SOLE |
| 87427V103 | TALK | TALKSPACE INC | $27.1M | 16.3% | 9,802,972 | Common | SOLE |
| 39957D201 | GROV | GROVE COLLABORATIVE HOLD INC | $4.8M | 2.91% | 3,225,097 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.